dextromethorphan hydrobromide/quinidine sulfate / Generic mfg. - LARVOL DELTA

Evaluating biodistribution of Zirconium-89 labeled brain derived exosomes in naïve mice comparing subpopulations using PET/CT (SNMMI 2025) - "2 NeuroDex Inc...Following IV injection, whole-body PET/CT scans were acquired using a 4-bed mouse hotel under isoflurane anesthesia... These findings highlight the impact of particle size and molecular composition on exosome biodistribution providing valuable insights for optimizing their use in diagnostics and therapeutics."

Preclinical • Anesthesia • ANXA5 • CD47

Evaluating biodistribution of Zirconium-89 labeled brain derived exosomes in naïve mice comparing subpopulations using PET/CT (SNMMI 2025) - "2 NeuroDex Inc...Following IV injection, whole-body PET/CT scans were acquired using a 4-bed mouse hotel under isoflurane anesthesia... These findings highlight the impact of particle size and molecular composition on exosome biodistribution providing valuable insights for optimizing their use in diagnostics and therapeutics."

Preclinical • Anesthesia • ANXA5 • CD47

Adaptive promising zone design for sequential parallel comparison design with continuous outcomes. (PubMed, Clin Trials) - "We also applied our findings to a real-world example from the AVP-923 trial in patients with Alzheimer's disease-related agitation, demonstrating the practical implications of adaptive sequential parallel comparison designs in clinical research...Although allocation ratio adjustments showed limited overall impact, they may be beneficial in specific scenarios. Future research should explore the application of these adaptive strategies to binary and survival outcomes in sequential parallel comparison designs."

Journal • Alzheimer's Disease • CNS Disorders

Sigma-1 receptors localize to C-boutons in lower motor neurons: a neuropathological study of bulbar and limb ALS (ALS-MND 2024) - "Recently, SIRs have increased interest and significance to the ALS field because one of the primary actions of dextromethorphan (e.g., NuedextaV R ), a treatment of ALS pseudobulbar affect, is as a S1R agonist. S1R is a strong marker of large neurons and especially motor neurons in spinal cord and cortex. S1R has a unique expression and localization with C-boutons specific to lower motor neurons. There are no neuropathological abnormalities of S1R that suggest primary involvement in ALS pathogenesis."

TARDBP

Assessing the efficacy of amyotrophic lateral sclerosis drugs in slowing disease progression: A literature review. (PubMed, AIMS Neurosci) - "These FDA-sanctioned treatments are Qalsody, Relyvrio, Radicava, Rilutek, Tiglutik, Exservan, and Nuedexta...However, despite these advancements in pharmaceutical interventions, finding a definitive cure for ALS remains a significant challenge. Continuous investigation into ALS pathophysiology and therapeutic avenues remains imperative, necessitating further research collaborations and innovative approaches to unravel the complex mechanisms underlying this debilitating condition."

Journal • Review • Amyotrophic Lateral Sclerosis • CNS Disorders

A Pilot Study to Evaluate the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease (AAN 2024) - "We hypothesize that dextromethorphan/quinidine (Nuedexta®) would decrease irritability in individuals with HD and minimize aggression and outbursts.Design/Randomized, double-blind, placebo-controlled, crossover, proof of concept study with 20 adults with verified HD mutation and irritability [defined as an Irritability Scale (IS) score > 14]...Although we observed a pronounced decrease in the IS score after the treatment with dextromethorphan/quinidine, our study revealed a strong placebo effect, and there was no difference between treatments."

Clinical • Huntington's Disease • Movement Disorders • Psychiatry

[Correction & Replacement] Dextromethorphan-Quinidine (Nuedexta) Improves Swallowing in Bulbar Onset ALS Patients with Pseudobulbar Affect - Pre-Post Observational Study in 86 ALS Patients (P4.4-019). (PubMed, Neurology) - No abstract available

Journal • Observational data

Evaluating the efficacy of dextromethorphan/quinidine (DM/Q) in treating irritability in Huntington’s disease (MDS Congress 2023) - "Although we observed a pronounced decrease in the IS score after the treatment with Nuedexta® (mean reduction of 8.8 points, or 32% compared to the baseline), our study revealed a strong placebo effect (mean decrease of 7.6 points, 27.5% with the placebo treatment) and there was no difference between treatments."

Clinical • Behavior Disorders • CNS Disorders • Psychiatry

ALSUntangled #71: Nuedexta. (PubMed, Amyotroph Lateral Scler Frontotemporal Degener) - "Nuedexta causes mild to moderate side effects. Based on this information, we support considering Nuedexta treatment for bulbar dysfunction in ALS patients with or without PBA."

Journal • Review

Neuron-derived extracellular vesicles blood-based diagnosis of synuclein TDP43 autophagy and synaptic dysfunction pathologies (AAIC 2023) - " NeuroDex developed two methods... Immunoaffinity isolation of EVs from plasma samples according to their cell of origin is a promising biomarker platform. We demonstrate the NDEs isolation selectivity, specificity, and precision. We also show the platform’s potential to identify pathologies like αSYN, TDP43, autophagy, and synaptic dysfunction; this reflects the potential for patient stratification."

Alzheimer's Disease • CNS Disorders • Dementia • Movement Disorders • Parkinson's Disease • TARDBP

Brexpiprazole (Rexulti) for agitation in Alzheimer's dementia. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Alzheimer's Disease • CNS Disorders • Dementia

Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease (clinicaltrials.gov) - P3 | N=20 | Completed | Sponsor: The University of Texas Health Science Center, Houston | Recruiting ➔ Completed

Trial completion • Genetic Disorders • Huntington's Disease • Movement Disorders

"$ZENV Zenvia Launches Chatbot Tool Integrated with ChatGPT #StockMarket https://t.co/ndfbB33m2x" (@stock_titan)

"$ZENV ZENVIA Reports Q4 & FY 2022 Results(1) https://t.co/PmOvfYUiRt" (@stock_titan)

"$ZENV Zenvia Informs Minimal Exposure to US Banks https://t.co/pNi9kbJbwl" (@stock_titan)

"$ZENV Zenvia launches integration of ChatGPT to its mass texting service solution https://t.co/d6fPcpCu7M" (@stock_titan)

BLOOD CELL-SPECIFIC EXTRACELLULAR VESICLES FOR BLOOD-BASED STRATIFICATION OF DEMENTIA PATHOLOGY (ADPD 2023) - "NeuroDex's novel EVs -based biomarkers constitute a platform that enables measuring different dementia - related pathologies. NeuroDex seems to identify the expected changes between diseases, and future studies will determine if co -morbidities can also be detected. We predict that dementia stratification based on pathology will boost therapeutic development."

Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Dementia • Movement Disorders • Multiple System Atrophy • Parkinson's Disease • TARDBP

Dextromethorphan/bupropion (Auvelity) for depression. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry • Tobacco Cessation

BLOOD-BASED DEMENTIA PATHOLOGY STRATIFICATION UTILIZING NEURON-DERIVED EXOSOMES. (CTAD 2022) - " NeuroDex’s blood assay is based on ExoSORT™, a proprietary immunoaffinity platform for isolating and characterizing neuronal extracellular vesicles (NDEs) from blood plasma... The methodology we developed to isolate and characterize plasma EVs opens a new avenue for neurodegenerative diagnosis. The ability to detect different dementia-associated pathologies by a single blood test can be a game-changer for clinical trials and diagnosis. When fully developed, our blood test could provide a tool to screen the elderly population for better prognosis and treatment selection."

Alzheimer's Disease • Amyloidosis • Amyotrophic Lateral Sclerosis • CNS Disorders • Dementia • Immunology • Inflammation • Lewy Body Disease • Multiple System Atrophy • Solid Tumor • NEFL • TARDBP

Biological aspects of nitrogen heterocycles for amyotrophic lateral sclerosis. (PubMed, Appl Microbiol Biotechnol) - "Currently, the Food and Drug Administration (FDA) approved drugs such as Radicava, Rilutek, Tiglutik, Exservan, and Nuedexta to treat ALS. • Neurodegenerative diseases and their drawbacks are discussed in detail. • Recent survey of nitrogen heterocycles in treating ALS disease are highlighted."

Journal • Review • Amyotrophic Lateral Sclerosis • CNS Disorders

"$ZENV ZENVIA Reports Q3 2022 Results https://t.co/oNBd4BHsqt" (@stock_titan)

Drugs for cognitive loss and dementia. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Alzheimer's Disease • CNS Disorders • Dementia

"$ZENV Zenvia Reports Q2 2022 Results https://t.co/28lENyxXEu" (@stock_titan)

"$ZENV ZENVIA Rings Opening Bell on Nasdaq https://t.co/jpVZdCZKbh" (@stock_titan)

"$ZENV ZENVIA Reports Preliminary Q2 2022 Results ahead of Investor Day https://t.co/cFjdKFlnWs" (@stock_titan)